Former NICE Exec Proposes New UK Fund For ‘High-Impact’ Drugs
Executive Summary
Some of the rebates paid by drug companies to the government on their sales of medicines could be placed in a central fund to pay for drugs of “demonstrable benefit,” according to Andrew Dillon.